Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
about
Immunological aspects in chronic lymphocytic leukemia (CLL) developmentCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseClinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.How I treat CLL up front.Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsThe novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?Antigen receptor stereotypy in chronic lymphocytic leukemia.The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone.Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma.IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.Chronic lymphocytic leukaemia
P2860
Q26865940-D7782AC0-F268-4BB4-9A86-B3307FC977B1Q27304652-44865D7A-842D-4933-B4F8-E141C625D056Q33856248-3EAE6E6A-E080-42A7-9E29-58CD20069D3BQ33878649-7E555DC4-C9E2-4D11-BD01-FE4DD36FAF8BQ33886052-A8EB5CB7-3208-4693-82E8-51FC871A61EBQ33965667-DC45C009-8A55-404F-941F-9033970DE9E7Q34056568-6AD8BE7E-9DD0-4351-8557-67FF78C0550BQ34095630-353E6418-1293-49D2-9923-AD53E74C74ACQ34137158-E83D51F9-F51D-4310-833B-D9CAC308DD4DQ35029461-BD7BAB44-BE3E-4490-8B97-D76E5E1BCF8FQ37335244-946A523D-02A7-421A-ABC2-1DAF32E7FE38Q37655012-44F48D19-4E35-45E9-9F3C-E55B18705B81Q37837955-7D88E792-3A8D-4CF6-8BCB-88C69D364B17Q38046045-40E0A961-9233-489A-B306-8ECD537690CDQ38088354-51B32E49-2F96-41D2-BEDE-552C021C99D1Q38998146-5A892526-AE1F-4B53-B68C-57CA3FF0FB36Q42325601-E8C16058-5B70-4C1D-9AC0-BCF9ADF2CE40Q42969236-229E183D-CF2D-46B2-8CE7-4B81A607DCC6Q44563802-AB629A0F-D742-41F9-9B97-11BC8D49594CQ52643368-4378BC3B-B0D0-4AD1-AD73-EFCC412B2408Q56270980-4ECDE880-2943-4A13-AD23-514FAF45139D
P2860
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@ast
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@en
type
label
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@ast
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@en
prefLabel
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@ast
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@en
P2093
P2860
P50
P1433
P1476
Use of IGHV3-21 in chronic lym ...... center leukemogenic selection.
@en
P2093
Andrew W Greaves
Emanuela M Ghia
George F Widhopf
Jennifer R Brown
John G Gribben
Kanti R Rai
Laura Z Rassenti
Neil E Kay
Sonia Jain
Thomas J Kipps
P2860
P304
P356
10.1182/BLOOD-2007-12-130229
P407
P577
2008-03-07T00:00:00Z